Preusser, M., Garde, J., Gion, M., Ruiz, M., García-Mosquera, J. J., Greil, R., Valero, M., Arumí, M., Raimondi, G., Campolier, M., Gonzalez-Alonso, P., Guerrero-Martinez, J. A., Llombart-Cussac, A., Oberndorfer, F., Marhold, M., Batista, M. V., Berghoff, A. S., Furtner, J., Fuereder, T., Bartsch, R. (2025). Patritumab deruxtecan (HER3-DXd) in active brain metastases (BM) from metastatic breast (mBC) and non–small cell lung cancers (aNSCLC), and leptomeningeal disease (LMD) from advanced solid tumors: Results from the TUXEDO-3 phase II trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.2005